# Placebo Controlled Phase IV Study to Compare the Efficacy and Safety of a Single Dose of Oral Talcid, a Single Dose of Oral Famotidine and a Single Dose of Placebo in Patients With Acute Heartburn Episodes

> **NCT01928888** · PHASE4 · COMPLETED · sponsor: **Bayer** · enrollment: 559 (actual)

## Conditions studied

- Heartburn

## Interventions

- **DRUG:** Talcid (Hydrotalcite, BAY4516H)
- **DRUG:** Famotidine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01928888
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05
- **Primary completion:** 2004-02
- **Final completion:** 2004-02
- **Target enrollment:** 559 (ACTUAL)
- **Last updated:** 2014-12-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01928888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01928888, "Placebo Controlled Phase IV Study to Compare the Efficacy and Safety of a Single Dose of Oral Talcid, a Single Dose of Oral Famotidine and a Single Dose of Placebo in Patients With Acute Heartburn Episodes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01928888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*